<i>ZNF76</i> predicts prognosis and response to platinum chemotherapy in human ovarian cancer

Hua, Tian; Wang, Ruimin; Zhang, Xiaochong; Zhao, Beibei; Fan, Shao-bei; Liu, Deng-Xiang; Wang, Wei

doi:10.1042/bsr20212026

Cited by 7 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We validated the differential expression of ZNF76-RI events between patients' CRC tissues and paracancerous tissues by RT-PCR, and the results were consistent with our bioinformatics analysis. Furthermore, consistent with our ndings, Tian et al also believe that ZNF76 may serve as a promising prognostic-related biomarker in cancer [35]. Our ndings suggest that alternative spliceosomes of ZNF76 and other ZNFs may play a potentially important role in the development of CRC.…”

Section: Discussionsupporting

confidence: 91%

Systematic profiling of alternative splicing of ZNF family in Colorectal cancer

Sun¹,

Zeng²,

et al. 2023

Preprint

View full text Add to dashboard Cite

Backgrounds: Colorectal cancer (CRC) is a global health issue that requires innovative prognostic signatures to improve patient outcomes. Alternative splicing (AS) of RNA is a crucial modification process involved in cancer progression, and zinc finger proteins (ZNFs), the largest family of DNA binding proteins, have been implicated in various aspects of cancer development. However, the role of ZNF AS events in cancer remains poorly understood. Methods: To address this, we investigated the relationship between ZNF AS and CRC development using clinical samples and bioinformatics approaches to identify a prognostic signature. Results: We identified 227 differentially expressed genes (DEGs) and 98 survival-related genes among ZNFs. We also identified 29 differentially expressed AS (DEAS) events and 93 survival-related AS events in CRC patients. Using these results, we developed a thirteen-AS signature that showed excellent predictive ability, with a 3-year area under the receiver operating characteristic (ROC) curve (AUC) value of 0.80, outperforming the commonly used tumor-node-metastasis (TNM) staging-based model (AUC = 0.73). Gene Set Enrichment Analysis (GSEA) showed that the risk score of our model was associated with various cancer-related pathways, including PI3K AKT MTOR, CELL CYCLE, APOPTOSIS, and more. We also validated our findings through qPCR and explored the correlations between splicing factors (SFs) and DEAS events. Conclusions: Our study provides new insights into the role of ZNFs in cancer and highlights their potential as prognostic biomarkers for CRC progression.

show abstract

Section: Discussionsupporting

confidence: 91%

Systematic profiling of alternative splicing of ZNF family in Colorectal cancer

Sun¹,

Zeng²,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that LSM2 plays a role in the disease progression of lung cancer [ 30 ]. Hua et al also found that LSM2 may be associated with the prognosis of ovarian cancer and may be involved in influencing the response to treatment with platinum-based drugs [ 31 ]. Abnormal expression of LSM4 is closely related to the occurrence and development of a variety of tumors.…”

Section: Discussionmentioning

confidence: 99%

Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma

Yang

Huang

Fan

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. The leading cause of cancer-related fatalities globally is lung cancer; lung adenocarcinoma (LUAD) is the most common histological type in it. The spliceosome plays an important role in a majority of malignancies. However, it is yet unclear how spliceosome-related genes affect patients with LUAD in terms of treatment course and prognosis. Methods. Spliceosome-related genes were assessed from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database to obtain clinical information and gene expression in patients with LUAD. A spliceosome-related gene signature and prognostic model were constructed by using the least absolute shrinkage and selection operator (LASSO), time-dependent receiver operating characteristic (ROC), and nomogram. Immune infiltrate levels, mutation analysis, and pathway enrichment were predicted potential mechanisms of the signature by using single-sample gene set enrichment analysis (ssGSEA), Gene Set Cancer Analysis (GSCA) database, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO) database. Then, a protein–protein interaction (PPI) network and transcription factor- (TF-) hub gene and drug mining network were also established by Cytoscape software. Results. Firstly, we constructed a prognostic model for 11 spliceosome signature genes. Based on the prognostic risk score, we stratified patients with LUAD into high- and low-risk groups. The high- and low-risk groups were closely related to the OS, tumor immune infiltration level, immune checkpoint molecules, and tumor mutation burden (TMB) of LUAD patients. Based on PPI networks, we also predict relevant TF genes that may regulate signature prognostic genes. Finally, drugs including oxaliplatin, arsenic trioxide, cisplatin, and sunitinib were excavated for the treatment of the 11 spliceosome signature genes in LUAD patients. Conclusion. In conclusion, this study is the first to explore the importance of spliceosome-related genes in the prognosis and treatment of LUAD. Through our study, we have innovatively provided potential prognosis genes and new therapeutic drug targets for the treatment of LUAD patients.

show abstract

“…14 Additionally, it has also been shown that PFDN6 expression is significantly associated with the prognosis of patients with ovarian cancer. 15 However, studies investigating the role of PFDN6 in CRC are limited. Therefore, an in-depth investigation of CRC will provide new insights into its clinical diagnosis and treatment.…”

Section: What This Study Addsmentioning

confidence: 99%

PFDN6 contributes to colorectal cancer progression via transcriptional regulation

Xu,

Kong,

Sun

et al. 2024

egastro

View full text Add to dashboard Cite

ObjectiveColorectal cancer (CRC) is a common cancer worldwide. Although there are several treatments for cancer, the therapeutic effect on CRC remains unsatisfactory, and it is imperative to identify new therapeutic targets.DesignPrefoldin (PFDN) is mainly used in the cytoskeleton assembly during the folding of actin and tubulin monomers. However, whether PFDN subunits are involved in regulating the development of CRC remains to be elucidated. In this study, molecular biology, cell culture, transcriptome sequencing and other experimental techniques, combined with bioinformatics, were used to verify the regulatory effects of PFDN6 on CRC.ResultsPFDN6 expression is elevated in patients with CRC and is closely associated with the development of CRC. Knockdown of PFDN6 reduced the tumour cell number, promoted apoptosis, and inhibited the migration and invasion of CRC cells in HCT-116 and RKO cell lines. Mechanistically, differentially expressed genes and related signalling pathways in RKO cells after PFDN6 knockdown were analysed by transcriptome sequencing.ConclusionPFDN6 was found to regulate the generation and development of CRC by targeting ZNF575. These results open new avenues for therapeutic interventions for patients with CRC.

show abstract

ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer

Cited by 7 publications

References 34 publications

Systematic profiling of alternative splicing of ZNF family in Colorectal cancer

Systematic profiling of alternative splicing of ZNF family in Colorectal cancer

Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma

PFDN6 contributes to colorectal cancer progression via transcriptional regulation

Contact Info

Product

Resources

About